HIGHBuilt-inProduct / Revenue mix
80%
Clinical Genomics consumables
“10-K Item 1: 'Approximately 80% of our Clinical Genomics revenues are from consumables used on a routine basis'”
MLAB · Concentration risk · 10-K extracted
Mesa Laboratories (MLAB) concentration risks
Updated
The most significant concentration Mesa Laboratories discloses is Clinical Genomics consumables at 80%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Mesa Laboratories’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 5 disclosed concentrations
HIGH1
MEDIUM2
LOW2
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
45%
other non-U.S. countries
“10-K Item 1A: 'we generated approximately 8% of our sales from operations in China and 45% of our sales from other non-U.S. countries, primarily in Europe'”
MEDIUMBuilt-inProduct / Revenue mix
30%
Dialyguard product line
“10-K Item 1A: 'Our Dialyguard product line accounts for approximately 30% of the revenues and one-third of gross profit margin associated with our Calibration Solutions division.'”
LOWOutside partyCustomer
20%
single customer (Clinical Genomics division)
“10-K Item 1: 'with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026'”
LOWBuilt-inGeographic
8%
China
“10-K Item 1A: 'we generated approximately 8% of our sales from operations in China'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Mesa Laboratories' concentration profile is layered across product mix and geography, with most exposures falling in the structural rather than dependency camp. Within its Clinical Genomics business, approximately 80% of revenues come from consumables used on a routine basis — a high-size, recurring-revenue-supportive concentration rather than a lumpy, project-based one. Geographically, the company draws approximately 45% of sales from non-U.S. countries other than China, primarily Europe, and a further 8% from China itself; both are structural, tying results to international demand and currency conditions rather than to any single account. Within Calibration Solutions, the Dialyguard product line contributes approximately 30% of that division's revenue and a third of its gross profit margin, another structural, product-mix concentration. The one dependency-type exposure is narrower: a single customer accounts for approximately 20% of the Clinical Genomics division's revenue, though this is disclosed at a low size band relative to the company as a whole. Netting these out, Mesa's risk is dominated by product-mix and geographic structure — consumables durability, international demand, and Dialyguard's contribution — with the single-customer dependency a smaller, secondary consideration layered on top.
For the engine’s reasoning on MLAB’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Scientific & Technical Instruments
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| BMI | Badger Meter, Inc. | 2 | 0 | 0 | 2 |
| MLAB● | Mesa Laboratories, Inc. | 1 | 2 | 2 | 5 |
| ESE | ESCO Technologies Inc. | 1 | 1 | 2 | 4 |
| COHR | Coherent Corp. | 1 | 1 | 0 | 2 |
| FTV | Fortive Corporation | 1 | 0 | 0 | 1 |
| CGNX | Cognex Corporation | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.